A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Live Conference Call and Webcast TODAY at 4:30 p.m. ETENGLEWOOD, Colo., May 11, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, provided today an overview of...
Confirms Accuracy using Frozen and Thawed Semen Samples, Increasing Potential UseClinical Results Presented at 111th American Urological Association Annual MeetingENGLEWOOD, Colo., May 10, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company...
ENGLEWOOD, Colo., May 6, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the closing of its previously announced underwritten public offering of...
Live Conference Call and Webcast Scheduled for May 11, 2016, at 4:30 p.m. ETENGLEWOOD, Colo., May 5, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology,...
ENGLEWOOD, Colo., May 2, 2016 -- Aytu BioScience, Inc. ("Aytu") (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced that it has priced an underwritten public offering of 18,750,000 shares...
Veteran Financial Executive Carl Dockery Joins AytuENGLEWOOD, Colo., April 13, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, announced today the appointment of Carl Dockery, a...
ENGLEWOOD, Colo., April 5, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, observed encouraging data from two prospective studies of its MiOXSYS™ System that demonstrated...
ENGLEWOOD, Colo., March 31, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on global commercialization of novel products in the field of urology, has obtained Health Canada Class II Medical Device approval for its...
ENGLEWOOD, Colo., March 29, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced that the company has entered into a co-promotion agreement for...
ENGLEWOOD, Colo., March 1, 2016 -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced that it has entered into a study agreement with Hybridyne Imaging...